Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix
Mar 23, 2021•37 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Kevin Hrusovosky’s career has been dedicated to transforming medicine from reactive “sick care” to preventative personalized care. A serial entrepreneur, he currently serves as the CEO of Quanterix, a company which has just nabbed $700 million and is raising the bar on proteomics testing.
“Genomics can tell you what your predisposition is,” he says in today’s interview, “proteomics can tell you the earliest moment you are in a disease cascade.”
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
“Genomics can tell you what your predisposition is,” he says in today’s interview, “proteomics can tell you the earliest moment you are in a disease cascade.”
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
For the best experience, listen in Metacast app for iOS or Android